Aldometanib (LXY-05-029) is a selective inhibitor of aldolase (ALDOA) with an IC50 of 50 uM in in vitro enzymatic assays. It also activates lysosomal AMPK by blocking FBP-aldolase binding, mimicking glucose starvation and improving metabolic health without causing hypoglycemia.